Cara Therapeutics Inc (NASDAQ: CARA) kicked off on Monday, up 6.26% from the previous trading day, before settling in for the closing price of $0.35. Over the past 52 weeks, CARA has traded in a range of $0.24-$3.03.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 115.17%. While this was happening, its average annual earnings per share was recorded 42.62%. With a float of $45.73 million, this company’s outstanding shares have now reached $54.48 million.
Let’s determine the extent of company efficiency that accounts for 55 employees. In terms of profitability, gross margin is 72.84%, operating margin of -946.87%, and the pretax margin is -1010.19%.
Cara Therapeutics Inc (CARA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cara Therapeutics Inc is 16.62%, while institutional ownership is 32.60%. The most recent insider transaction that took place on Aug 01 ’24, was worth 1,452. In this transaction PRESIDENT AND CEO of this company sold 4,149 shares at a rate of $0.35, taking the stock ownership to the 172,436 shares. Before that another transaction happened on May 02 ’24, when Company’s PRESIDENT AND CEO sold 3,936 for $0.75, making the entire transaction worth $2,952. This insider now owns 176,585 shares in total.
Cara Therapeutics Inc (CARA) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.52 earnings per share (EPS), higher than consensus estimate (set at -0.52) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.62% per share during the next fiscal year.
Cara Therapeutics Inc (NASDAQ: CARA) Trading Performance Indicators
Take a look at Cara Therapeutics Inc’s (CARA) current performance indicators. Last quarter, stock had a quick ratio of 4.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.04, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -0.73 in one year’s time.
Technical Analysis of Cara Therapeutics Inc (CARA)
Looking closely at Cara Therapeutics Inc (NASDAQ: CARA), its last 5-days average volume was 0.51 million, which is a drop from its year-to-date volume of 0.7 million. As of the previous 9 days, the stock’s Stochastic %D was 85.21%. Additionally, its Average True Range was 0.03.
During the past 100 days, Cara Therapeutics Inc’s (CARA) raw stochastic average was set at 18.41%, which indicates a significant decrease from 96.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.16% in the past 14 days, which was lower than the 130.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3280, while its 200-day Moving Average is $0.6733. However, in the short run, Cara Therapeutics Inc’s stock first resistance to watch stands at $0.3829. Second resistance stands at $0.3959. The third major resistance level sits at $0.4199. If the price goes on to break the first support level at $0.3459, it is likely to go to the next support level at $0.3219. Now, if the price goes above the second support level, the third support stands at $0.3089.
Cara Therapeutics Inc (NASDAQ: CARA) Key Stats
The company with the Market Capitalisation of 20.28 million has total of 54,676K Shares Outstanding. Its annual sales at the moment are 20,970 K in contrast with the sum of -118,510 K annual income. Company’s last quarter sales were recorded 990 K and last quarter income was -20,020 K.
